Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Codexis, Inc.NASDAQ: CDXS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $11.94M rose 148.1% year over year, ahead of the +83.9% change in trailing-twelve-month gross profit. Sequentially, it fell 66.4% from the prior quarter. Over 3 fiscal years it compounded at -15.3% a year.

Context

  • Gross profit amounted to 86.7% of revenue in FY2025, up 14.2 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +148.1% holds above the trailing-twelve-month pace of +83.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.94M-66.4% QoQ
Last fiscal yearDec 2025
$61.05M+41.8% YoY
LTMMar 2026
$65.55M+83.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+148.1%——
1 year+41.8%——
3-year CAGR-15.3%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
61.05M USD
Year-over-year change
+41.8%
4-year CAGR
-7.3%

Gross Profit vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +83.9% is the 2nd highest of 9, against a peer median of -40.7%.
  • Gross profit amounts to 83.9% of revenue for CDXS, versus a peer median of 93.4%.
CDXS Competitors
Gross Profit for CDXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CDXSCodexis, Inc.LTM Mar 2026$65.55M USD+83.9%-15.3%83.9%
IVVDInvivyd, Inc.LTM Mar 2026$51.41M USD+50.2%—92.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$34.56M USD-45.8%-31.5%100.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$33.06M USD-2.5%-3.5%94.8%
OABIOmniAb, Inc.LTM Mar 2026$10.25M USD-61.7%—35.5%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$3.01M USD+150.7%—94.9%
IPHAInnate Pharma S.A.FY2025€2.79M EUR-77.9%-22.6%100.0%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.14M USD-35.6%—72.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$379.5K USD-81.2%—19.5%
TARAProtara Therapeutics, Inc.LTM Mar 2026-$90K USD———
Peer median (excluding CDXS) —-40.7%-22.6%93.4%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue104.75M138.59M70.14M59.35M70.39M
Cost of Revenue22.21M38.03M12.81M16.29M9.34M
Gross Profit82.55M100.56M57.33M43.06M61.05M
Gross Margin78.8%72.6%81.7%72.6%86.7%
Research & Development55.92M80.1M58.89M46.26M52.31M
Selling, General & Admin49.32M52.17M53.25M55.15M47.07M
Operating Expenses105.24M135.44M125.4M101.58M99.38M
Depreciation & Amortization5.95M5.4M5.52M4.95M5.25M
EBITDA(15.14M)(26.31M)(49.28M)(53.41M)(33.87M)
EBITDA Margin-14.5%-19.0%-70.3%-90.0%-48.1%
Operating Income(22.7M)(34.88M)(68.07M)(58.52M)(38.33M)
Operating Margin-21.7%-25.2%-97.0%-98.6%-54.5%
Interest Income459K1.44M4.17M3.67M2.63M
Interest Expense00004.81M
Other Income / Expenses1.61M1.57M(8.1M)(6.72M)(5.6M)
Income Before Tax(21.09M)(33.32M)(76.17M)(65.24M)(43.93M)
Pre-Tax Margin-20.1%-24.0%-108.6%-109.9%-62.4%
Income Tax Expense189K276K69K34K47K
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Net Margin-20.3%-24.2%-108.7%-110.0%-62.5%
EPS (Basic)(0.33)(0.51)(1.12)(0.89)(0.50)
EPS (Diluted)(0.33)(0.51)(1.12)(0.89)(0.50)
Weighted Avg Shares64.57M65.34M68.13M73.41M87.14M
Weighted Avg Shares (Diluted)64.57M65.34M68.13M73.41M87.14M

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.